Latest ArticlesCongenital plasminogen deficiency (C-PLGD), also referred to as type Ⅰ plasminogen deficiency, plasminogen deficiency or hypoplasminogenemia, is an ultra-rare autosomal recessive disorder of the fibrinolytic system, which is mainly manifested by the abnormal extravascular accumulation and growth of fibrin-rich, ligneous pseudomembranous lesions on mucous membranes throughout the body. Left untreated, these lesions may impair normal tissue and organ function, and impact patients' quality of life. Currently, there is no specific replacement therapy approved for the treatment of C-PLGD in China. As such, treatment options have been limited to non-specific therapies and interventions, including surgery, all of which have been proved to be less effective. Foreign clinical trials have shown that replacement therapy with human glutamate-plasminogen can consistently increase plasminogen activity and improve the clinical symptoms of C-PLGD patients, and it is well tolerated. This article provided an overview of the research progress on the treatment of C-PLGD with human plasminogen, in order to provide some ideas and basis for its clinical application and research in the treatment of plasminogen deficiency.
Hemophilia A (HA) is a rare X-chromosome linked recessive hemorrhagic disorder caused by the deficiency or dysfunction of coagulation factor Ⅷ (FⅧ) in the blood. The incidence of HA is low, the cost of treatment is high, and there is no effective radical treatment at present. On-demand alternative treatment is still the most effective way to treat HA in our country. However, HA patients need lifelong medication, the existing drugs have short half-life, high injection frequency, easy to produce coagulation FⅧ inhibitors, and poor quality of life of patients. In view of such unmet clinical needs, this paper mainly reviewed the clinical research progress of three alternative therapeutic drugs: plasma-derived human coagulation FⅧ, recombinant human coagulation FⅧ and long-acting recombinant human coagulation FⅧFc fusion protein, to provide new ideas and basis for later drug development and clinical treatment.
To investigate the mechanism of Xiaochaihu decoction combined with Danggui Shaoyao powder in the treatment of Hashimoto's thyroiditis (HT) based on network pharmacology and molecular docking techniques.
Traditional Chinese medicine (TCM) system pharmacology and TCMSP database were used to screen the main active components of 13 TCM compounds and their action targets. OMIM and GeneCards databases were used to screen the HT targets. Cytoscape 3.9.1 was used to construct the TCM-component-target network diagram and protein-protein interaction network diagram, and screen the key targets. The Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis were conducted for the intersection targets through the DAVID database. Molecular docking was carried out by AutoDock Vina, preliminary screening and further verification of the core chemical components of the compound.
A total of 190 active ingredients were obtained, including quercetin, luteolin and kaempferol. There were 292 component targets, 2 132 disease targets and 171 intersection targets. The main key targets were tumor protein p53, mitogen-activated protein kinase (MAPK)3 and protein kinase B. This compound may play a therapeutic role in HT by regulating MAPK, interleukin-17, tumor necrosis factor and other signaling pathways.
The core components of Xiaochaihu decoction and Danggui Shaoyao powder may be quercetin, luteolin, kaolin and baicalin, which may play a therapeutic role in HT by regulating tumor-related signaling pathways.
To observe the effect of polysaccharide iron complex capsule combined with compound ferrous sulfate folic acid tablet on pregnant women with iron deficiency anemia during pregnancy (IDA).
A total of 114 pregnant women with IDA admitted to our hospital from January 2022 to April 2023 were divided into observation group and control group, with 57 cases in each group. The control group was given polysaccharide iron complex capsules, and the observation group was given compound ferrous sulfate folic acid tablets on the basis of the control group. The curative effect, anemia, iron metabolism indexes, immune function, safety indicators and adverse reactions of two groups were compared.
After treatment, red blood cell count, hemoglobin, hematocrit, serum ferritin, serum iron, CD3+, CD4+ and CD4+/CD8+ were significantly increased in both groups, and the observation group was higher than the control group, and the transferrin and CD8+ were significantly decreased than before treatment, and the observation group was lower than the control group (P<0.05). The total effective rate of observation group (55/57, 96.49%) was higher than that of control group (47/57, 82.46%, P<0.05).
Polysaccharide iron complex capsule combined with compound ferrous sulfate folic acid tablet has a good effect on IDA.
To investigate the effect of Fuzheng Yiliu Fang combined with mFOLFOX6 chemotherapy on the clinical benefit rate and intestinal flora of patients with colon cancer.
A total of 106 patients with advanced colon cancer admitted to our hospital from February 2021 to May 2023 were selected and divided into chemotherapy group (mFOLFOX6 chemotherapy) and combination group (combined with Fuzheng Yiliu Fang on the basis of chemotherapy group) according to random number table method, with 53 cases in each group. The efficacy, intestinal flora, immune indexes and incidence of adverse reactions were compared between the two groups.
The clinical benefit rate of combination group (84.31%) was higher than that of chemotherapy group (64.00%, P<0.05). After treatment, the number of Bifidobacterium and Lactobacillus in combination group was higher than before treatment and higher than that in chemotherapy group (P<0.05), and the number of Escherichia coli was lower than before treatment and higher than that in chemotherapy group (P<0.05). After treatment, the levels of CD4+ and CD4+/CD8+ in combination group were higher than those in chemotherapy group, and CD8+ was lower than that in chemotherapy group (P<0.05). The incidence of gastrointestinal reaction (29.41%) and myelosuppression (13.73%) in combination group were lower than those in chemotherapy group (66.00%, 32.00%, P<0.05).
Fuzheng Yiliu Fang combined with mFOLFOX6 can effectively regulate intestinal flora, significantly reduce the impact of chemotherapy on immune function, significantly reduce gastrointestinal reactions, bone marrow suppression and other adverse reactions of chemotherapy in the treatment of advanced colon cancer patients, and help to improve the clinical benefit rate.
To investigate the efficacy of sulfasalazine suppositories combined with Yuyang decoction enema in the treatment of rectal ulcerative colitis (UC), and the influences on serum soluble triggering receptor expressed on myeloid cells -1 (sTREM-1) and interleukin-10 (IL-10).
A total of 144 patients with rectal UC admitted to our hospital from January 2020 to July 2022 were divided into control group and study group by random number table method, with 70 cases in each group. The control group was treated with sulfasalazine suppositories and the study group was treated with sulfasalazine suppositories combined with Yuyang decoction enema. The therapeutic effect, serum sTREM-1, IL-10, symptom score and Baron endoscopy score were compared between the two groups.
The total effective rate of the study group was higher than that of the control group (P<0.05). After treatment, serum sTREM-1, symptom score and Baron endoscopy score of patients in both groups were lower than before treatment, and serum IL-10 level was increased, and the improvement was more obvious in the study group (P<0.05). The total incidence of adverse reactions in the control group and the study group were 2.86% and 10.00%, respectively, and there was no significant difference (P>0.05).
Sulfasalazine suppositories combined with Yuyang decoction enema has an obvious effect in the treatment of rectal UC patients. It can obviously inhibit the expression of serum sTREM-1, improve patients' intestinal inflammatory reaction, and reduce symptom score and Baron endoscopy score.
To evaluate the efficacy and safety of nafamostat mesylate (NM) in hyperbilirubinemia patients with hepatic failure (HF) treated with artificial liver support system (ALSS).
A total of 54 HF patients who received ALSS in our hospital from September 2020 to March 2023 were selected, of which 28 were treated with NM anticoagulation and 26 were treated with low molecular weight heparin (LMWH). All patients received two treatments, each lasting 3 hours. Hemodialyzer coagulation, bleeding complications, adverse reactions, total bilirubin (TBil) reduction rate, 30, 90 days survival rate were observed and measured.
There was no significant difference in blood flow rate between the two groups (P>0.05). After treatment, there was no significant difference in the reduction rate of TBil in the NM group compared with the LMWH group [(60.43±6.29)% vs (61.27%±6.45)%, P>0.05]. There were no significant differences in dialyzer coagulation, red blood cell transfusion, hypotension, 30, 90 days survival rate and nausea and vomiting between the two groups (P>0.05). There was no gastrointestinal bleeding in the NM group, and 4 cases in the LMWH group, the difference was statistically significant (P<0.05).
Compared with LMWH, NM does not increase the risk of bleeding in HF patients undergoing ALSS, and is a safe and effective anticoagulant.
To investigate the effects of imrecoxib combined with methotrexate (MTX) on serum vascular endothelial growth factor (VEGF), erythrocyte sedimentation rate (ESR), recombinant Dickkopf related protein 1 (DKK-1), and bone metabolism in patients with ankylosing spondylitis (AS).
A total of 113 patients with AS admitted in the rheumatology and immunology department of our hospital from June 2020 to June 2022 were selected and randomly divided into experimental group (imrecoxib+MTX, n=57) and control group (MTX, n=56) using a random number table method. The clinical efficacy, serum VEGF, ESR, DKK-1, bone metabolism indexes (bone gla protein (BGP), bone alkaline phosphatase (BALP)), and Bath AS disease activity index (BASDAI) scores, finger-ground distance, and incidence of complications between two groups were compared.
After treatment, the total effective rate of experimental group was higher than that of control group (91.23% vs 76.79%, P<0.05). Serum ESR and DKK-1 protein levels in two groups were lower than before, and experimental group was lower than control group (P<0.05). Serum VEGF level in experimental group was higher than that in control group (P<0.05). After treatment, serum BGP and BALP levels in both groups were increased, and the levels in experimental group were higher than those in control group. And C-reactive protein (CRP) level in both groups were lower than before treatment, and the experimental group was lower than that in control group (P<0.05). BASDAI score and finger-ground distance in both groups were lower than before, and the experimental group was lower than the control group (P<0.05). There was no significant difference in adverse reactions between the two groups (P>0.05).
The combination of imrecoxib and MTX is effective in the treatment of AS, can improve bone metabolism levels, and is worthy of clinical promotion and application.
To investigate the relationship between poor living habits, environment and pregnancy outcome in elderly pregnant women with gestational diabetes mellitus (GDM).
A retrospective study was conducted to select elderly pregnant women with GDM who gave birth in Maternal and Child Health Care Hospital from September 2022 to September 2023 as the study objects. Data were collected through questionnaires and multivariate Logistic regression was used to analyze the influence of adverse lifestyle habits on pregnancy outcomes in elderly pregnant women with GDM.
There were 202 pregnant women with GDM, with an average age of (37.5±2.2) years and 18.3% age≥40 years. Among the 52 cases, 61 adverse pregnancy outcomes occurred, the incidence rate was 25.7%, including 19 cases of premature rupture of membranes, 14 cases of macrosomia, 11 cases of primipara cesarean section, 7 cases of premature delivery, 5 cases of low birth weight, 3 cases of postpartum hemorrhage and 2 cases of neonatal asphyxia. Logistic regression analysis showed that age≥40 years old and insufficient sleep were risk factors for adverse pregnancy outcomes (odds ratio values were 2.11 and 2.43, respectively).
As an interventionable lifestyle, sleep should be included in the routine work of pregnancy and perinatal health care, and full attention should be paid to elderly pregnancies, which is of great significance for reducing adverse pregnancy outcomes in elderly GDM pregnant women.
To investigate the clinical effect of low-dose dexamethasone combined with anti-tuberculosis therapy on tuberculous meningitis (TBM) complicated with type 2 diabetes mellitus (T2DM).
86 TBM patients with T2DM were divided into two groups by random number table method, with 43 cases in each group. The control group was treated with conventional dose dexamethasone combined with anti-tuberculosis therapy, and the observation group was treated with low-dose dexamethasone combined with anti-tuberculosis therapy. The clinical efficacy, duration of symptom resolution, cerebrospinal fluid biochemistry, blood glucose homeostasis, interleukin-33 (IL-33) and adenosine deaminase (ADA) levels and adverse reactions were compared between the two groups.
There were no significant differences in the total effective rate, cerebrospinal fluid biochemistry, cerebrospinal fluid IL-33 and ADA levels between the two groups (P>0.05). Compared with before treatment, fasting blood glucose, fasting islet, insulin resistance index (homeostasis model assessment of insulin resistance, HOMA-IR) and glycosylated hemoglobin levels in control group were increased, and the differences were statistically significant (P<0.05), while there was no significant difference in observation group after treatment (P>0.05). Symptom disappearance time in observation group was longer than that in control group, and the incidence of adverse reactions was lower than that in control group (P<0.05).
Low-dose dexamethasone combined with anti-tuberculosis treatment for TBM patients with T2DM can stabilize blood sugar, reduce the levels of IL-33 and ADA in cerebrospinal fluid and adverse reactions.